Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, June 3, 2014, 107 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $420.42 to $5,791,625.60.

Highlighted Stocks Traded by Insiders:

CareFusion (CFN) - FREE Research Report

Leonard Thomas J, who is President, Medical Systems at CareFusion, sold 1,250 shares at $42.81 on June 3, 2014. Following this transaction, the President, Medical Systems owned 33,303 shares meaning that the stake was reduced by 3.62% with the 1,250-share transaction.

The shares most recently traded at $43.61, up $0.80, or 1.83% since the insider transaction. Historical insider transactions for CareFusion go as follows:

  • 4-Week # shares sold: 2,158
  • 12-Week # shares sold: 4,658
  • 24-Week # shares sold: 71,654

The average volume for CareFusion has been 1.6 million shares per day over the past 30 days. CareFusion has a market cap of $8.9 billion and is part of the health care sector and health services industry. Shares are up 8.16% year-to-date as of the close of trading on Tuesday.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. The company has a P/E ratio of 24.0. Currently, there are 5 analysts who rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFN - FREE

TheStreet Quant Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full CareFusion Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ensco (ESV) - FREE Research Report

Rabun Daniel Wayne, who is Director at Ensco, sold 50,000 shares at $52.64 on June 3, 2014. Following this transaction, the Director owned 202,129 shares meaning that the stake was reduced by 19.83% with the 50,000-share transaction.

The shares most recently traded at $53.04, up $0.40, or 0.75% since the insider transaction. Historical insider transactions for Ensco go as follows:

  • 4-Week # shares sold: 50,000
  • 12-Week # shares sold: 50,000
  • 24-Week # shares sold: 60,813

The average volume for Ensco has been 2.9 million shares per day over the past 30 days. Ensco has a market cap of $12.3 billion and is part of the basic materials sector and energy industry. Shares are down 6.59% year-to-date as of the close of trading on Tuesday.

Ensco plc provides offshore contract drilling services to the oil and gas industry worldwide. The company operates through three segments: Floaters, Jackups, and Other. The stock currently has a dividend yield of 5.24%. The company has a P/E ratio of 8.8. Currently, there are 4 analysts who rate Ensco a buy, 2 analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ESV - FREE

TheStreet Quant Ratings rates Ensco as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Ensco Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

HCP (HCP) - FREE Research Report

Rhein Peter L, who is Director at HCP, sold 5,000 shares at $41.89 on June 3, 2014. Following this transaction, the Director owned 25,700 shares meaning that the stake was reduced by 16.29% with the 5,000-share transaction.

Young Kendall K, who is Executive Vice President at HCP, sold 5,114 shares at $42.12 on June 3, 2014. Following this transaction, the Executive Vice President owned 26,898 shares meaning that the stake was reduced by 15.98% with the 5,114-share transaction.

The shares most recently traded at $41.71, down $0.41, or 0.98% since the insider transaction. Historical insider transactions for HCP go as follows:

  • 4-Week # shares sold: 20,755
  • 12-Week # shares sold: 20,755
  • 24-Week # shares sold: 20,755

The average volume for HCP has been 2.9 million shares per day over the past 30 days. HCP has a market cap of $19.3 billion and is part of the financial sector and real estate industry. Shares are up 16.11% year-to-date as of the close of trading on Tuesday.

HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. The stock currently has a dividend yield of 5.19%. The company has a P/E ratio of 21.3. Currently, there are 3 analysts who rate HCP a buy, 2 analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HCP - FREE

TheStreet Quant Ratings rates HCP as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, expanding profit margins, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full HCP Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null